However, in the chronic lymphocytic leukemia cell model, PTPN1 could disrupt the degradation of Bcr‐Abl protein mediated by synthetic steroidal glycoside SBF‐1 via the lysosome pathway, which leads to the resistance of K562 cells to imatinib.39 This evidence concerns the gene ABL1 and B-cell chronic lymphocytic leukemia.